Ambrx Pipeline

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on “best in class” biopharmaceutical product opportunities. Through the application of protein medicinal chemistry™, Ambrx has been able to create molecules optimized for efficacy, convenience, and tolerability/safety. Our lead program ARX-201, is a long-acting human growth hormone (hGH) that is currently in phase II clinical trials. ARX-201 is administered once-weekly, a notable improvement over current once-daily hGH therapies. Our second most advanced project is ARX424 for the treatment of multiple sclerosis. ARX424 has demonstrated enhanced in vivo potency (> 2-fold) and pharmacokinetics (19-fold increased exposure) when compared to marketed products from this class of proteins. These programs are partnered with EMD Serono. Our lead, wholly-owned product candidate is ARX618, a long-acting variant of FGF21 which has demonstrated retained potency and extended pharmacokinetics when compared to wild-type FGF21. ARX618 is currently in preclinical development for diabetes. Additional protein and antibody drug conjugate-based product candidates targeting cancer and obesity are advancing towards clinical development. We expect to have two clinical stage programs by late-2010.

Click on image to enlarge.